Is survodutide better than tirzepatide?

There is no head-to-head result to rank them. Tirzepatide is approved; survodutide is investigational.

Survodutide vs Tirzepatide: Glucagon vs GIP Partners

Survodutide vs tirzepatide: an investigational GLP-1/glucagon agonist vs approved GLP-1/GIP tirzepatide. Status and report links. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Tirzepatide (Mounjaro, Zepbound) is an approved GLP-1/GIP dual agonist. Survodutide pairs GLP-1 with glucagon receptor activity instead of GIP and remains investigational. Glucagon activity is being studied for liver-fat and energy-expenditure effects. No head-to-head trial result is summarised here. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

What users report here

Anonymous accounts are collected on the Tirzepatide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.

More confessions from the archive

Community Q&A

Is survodutide better than tirzepatide?: There is no head-to-head result to rank them. Tirzepatide is approved; survodutide is investigational.
What does survodutide target?: GLP-1 and glucagon receptors.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Sources

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.